NanoDimension is a venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
NanoDimension is a leading venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences. We focus on early stage opportunities in the US and Europe led by exceptional entrepreneurs. NanoDimension’s investment team takes an active approach to building portfolio companies, leveraging our expertise and network to find and build companies with innovative solutions to critical global problems.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2021 | Icosavax | Series B | 0 |
12/2010 | View | Series C | 40M |
2/2017 | Tarveda Therapeutics | Series D | 30M |
5/2014 | Twist Bioscience | Series B | 26M |
12/2018 | Inscripta | Series C | 0 |
2/2018 | Inscripta | Series C | 55.5M |
8/2018 | SQZ Biotech | Series C | 0 |
12/2019 | Arctos Medical | Seed Round | 0 |
3/2008 | Xtellus | Venture Round | 8.3M |
10/2019 | Icosavax | Series A | 0 |
1/2010 | SBA Materials | Venture Round | 5.2M |
6/2015 | Twist Bioscience | Series C | 37M |
10/2016 | Emulate | Series B | 0 |
2/2016 | ARMO BioSciences | Series C | 50M |
8/2017 | ARMO BioSciences | Series C | 0 |
7/2020 | Natron Energy | Series D | 0 |
11/2007 | BIND Therapeutics | Series B | 16M |
2/2018 | H55 | Venture Round | - |
5/2010 | Crocus Technology | Series C | 0 |
6/2012 | View | Series D | 0 |
1/2016 | Twist Bioscience | Series D | 61M |
1/2016 | Pulse Therapeutics | Venture Round | 10M |
7/2014 | Emulate | Series A | 12M |
2/2017 | Inscripta | Series B | 23M |
1/2012 | Tarveda Therapeutics | Series A | 2.8M |
5/2014 | ARMO BioSciences | Series B | 30M |
6/2015 | Crocus Technology | Series E | 21M |
7/2013 | Crocus Technology | Series D | 0 |
4/2010 | Selecta Biosciences | Series C | 15M |
4/2019 | Inscripta | Series C | 0 |
1/2015 | Tarveda Therapeutics | Series B | 21M |
11/2013 | View | Venture Round | 12.6M |
10/2008 | Crocus Technology | Series B | 15.9M |
7/2018 | Serotiny | Seed Round | 3M |
9/2019 | Amphivena Therapeutics | Series C | 0 |
9/2015 | Selecta Biosciences | Series E | 38M |
10/2014 | Selecta Biosciences | Private Equity Round | 20M |
9/2016 | SQZ Biotech | Series B | 16M |
6/2010 | BIND Therapeutics | Series C | 12.4M |
5/2020 | SQZ Biotech | Series D | 0 |
2/2009 | Selecta Biosciences | Series B | 15.1M |
12/2013 | Tarveda Therapeutics | Series B | 21M |
4/2021 | Icosavax | Series B | 0 |
7/2020 | Natron Energy | Series D | 0 |
5/2020 | SQZ Biotech | Series D | 0 |
12/2019 | Arctos Medical | Seed Round | 0 |
10/2019 | Icosavax | Series A | 0 |
9/2019 | Amphivena Therapeutics | Series C | 0 |
4/2019 | Inscripta | Series C | 0 |
12/2018 | Inscripta | Series C | 0 |
8/2018 | SQZ Biotech | Series C | 0 |
7/2018 | Serotiny | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|